Highlights Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Real-time Estimate Cboe BZX Other stock markets 15:00:17 10/05/2024 BST			5-day change	1st Jan Change
3.345 ^USD	-22.03%		-6.46%	-57.96%

05-09	Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	MT
05-09	Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	05-09	MT
AbbVie raises annual profit forecast on strong Skyrizi sales	04-26	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-12	CI
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	02-28	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	02-28	CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Revance Therapeutics Gets Permanent J-Code for Daxxify	02-02	DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02-02	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02-02	RE
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	12-12	MT
US Consumer group seeks stronger warnings on Botox, similar treatments	12-12	RE
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q3 Revenue $56.8M, vs. Street Est of $58.7M	11-08	MT
Revance's Botox rival gets FDA approval for painful neck muscle condition	14/08/23	RE
U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	14/08/23	CI
Revance Therapeutics' Q2 Net Loss Narrows, Revenue Increases	09/08/23	MT
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q2 Revenue $58.1M, vs. Street Est of $58.9M	08/08/23	MT
Revance Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Revance Therapeutics' Q1 Net Loss Narrows, Revenue Climbs	09/05/23	MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Highlights

Filters